Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
2.950
-0.155 (-4.99%)
Dec 20, 2024, 4:00 PM EST - Market closed
Soligenix Employees
As of December 31, 2023, Soligenix had 15 total employees, including 13 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$24,279
Profits / Employee
-$473,274
Market Cap
7.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Trinity Biotech | 380 |
XWELL | 337 |
Biofrontera | 85 |
Mustang Bio | 80 |
Genprex | 26 |
Elevai Labs | 18 |
Cyclerion Therapeutics | 1 |
SNGX News
- 5 days ago - Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 19 days ago - HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - PRNewsWire
- 4 weeks ago - Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 5 weeks ago - Soligenix to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 5 weeks ago - Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - PRNewsWire
- 6 weeks ago - Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - PRNewsWire
- 2 months ago - Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin - PRNewsWire
- 2 months ago - Soligenix Invited to Present at Upcoming Investor Conferences - PRNewsWire